Back

B Lymphocyte Protein Factories produced by Hematopoietic Stem Cell Gene Editing

Hartweger, H.; Ruprecht, C.; Yao, K.-H.; Laffont, P.; Lima dos Reis, G.; Zhou, P.; Hägglöf, T.; Binet, L.; Loewe, M.; Hong, J. P.; Xiao, T.; Sefik, E.; Hernandez, B.; Gazumyan, A.; Jankovic, M.; Seaman, M. S.; Costa, G.; Nelson, S. A.; Clark, J.; Kanatani, S.; Wilson, P. C.; Krammer, F.; Levashina, E. A.; Julien, J.-P.; Wardemann, H.; Sinnis, P.; Stamatatos, L.; Flavell, R. A.; Nussenzweig, M. C.

2026-01-18 immunology
10.64898/2026.01.16.699998 bioRxiv
Show abstract

Long-term in vivo production of therapeutic proteins and development of vaccines that elicit protective levels of broadly neutralizing antibodies (bNAbs) against major pathogens face challenges. Here we report on an alternative gene-editing approach using small numbers of hematopoietic stem and progenitor cells (HSPCs) to direct long-term, high-level expression of antibodies or cargo proteins. Edited B lymphocyte offspring can be activated by cognate antigen to undergo clonal expansion and develop into specific antibody or cargo protein-synthesizing plasma cells. These cells produce long-lasting, therapeutic levels of serum antibody against HIV-1 or malaria and an anti-influenza virus bNAb that mediated universal protection from heterologous lethal challenge. Our data provide a paradigm for cell therapy approaches to prevent or treat disease using self-amplifying B cell protein factories.

Published in Science (predicted rank #2) · training set

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.